Clinical Trials Browser

Withdrawn × Breast Neoplasms × liposomal doxorubicin × Clear all

NCT00434031 2012-07-30

CETRA

Phase 2 Withdrawn

Breast Neoplasms

NCT01333423 2012-06-26

Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1 Withdrawn

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms